Skip to content
Lawmakers questioned Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on key issues like vaccines, biosecurity, and federal research funds in a […]
Lawmakers question Kennedy on vaccines, biosecurity, and NIH cuts Read More »
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s “MAHA Report: Make Our Children Healthy Again,” released May 22, identifies the Trump administration’s
MAHA report takes issue with industry-funded research Read More »
The Food and Drug Administration (FDA) added to a small list of gene-edited animals that can be used in the food supply chain with
FDA approves pig genetically engineered to resist disease Read More »
Tariffs on pharmaceuticals would harm supply chains that ensure we have enough medicines while threatening America’s security, economy, and biotech leadership, the Biotechnology Innovation
BIO’s comments on tariffs: There are better ways to strengthen U.S. biotech Read More »
Speaking on a recent Endpoints News panel, Nkarta CEO Paul Hastings discussed the impact of regulatory uncertainty and federal funding cuts on the investment
Nkarta’s Hastings discusses environment for biotech funding in Endpoints panel Read More »
America has long been the global leader in rare disease drug development but this leadership is at risk unless Congress protects key incentives In
U.S. leadership in rare disease drugs at risk, BIO expert tells Orphan Drug Congress Read More »
The May 1 reintroduction of two bills designed to strengthen the certainty of U.S. patents earned praise from the Biotechnology Innovation Organization (BIO). The
BIO applauds reintroduction of two bills aimed at patent reform Read More »
Safeguarding human health during clinical research is critically important, but biotechnology has shown that this does not always have to mean using animals to
BIO report outlines use of NAMs to reduce animal testing Read More »
“Data makes you credible; stories make you memorable,” began Amy Niles, Chief Mission Officer of the PAN Foundation, during the Biotechnology Innovation Organization’s (BIO)
Show Me the Evidence: Data to Understand and Break Down Patient Access Barriers! Read More »
Given the importance of intellectual property for biotech, the Biotechnology Innovation Organization (BIO) remains vigilant in ensuring IP is protected. In recognition of World
BIO IP expert reviews the current policy landscape Read More »
